Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE015 (POL) (Dr. Ito)
· consented 2022-02-15
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-05-31 (study day 89); relationship: N
mild
assessed
2026-08-18
Grade 1 Adrenal insufficiency — outcome: RECOVERED/RESOLVED; onset 2022-06-24 (study day 113); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-08-15 (study day 165); relationship: Y
mild
assessed
2026-08-18
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-08-26 (study day 176); relationship: N
moderate
assessed
2026-08-18
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-08-31 (study day 181); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-02 (study day 244); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.